IGC Pharma completes enrollment in Phase 2 CALMA Alzheimer’s agitation trial, expects topline data in Q4 2026

PUBT · 1d ago
IGC Pharma completes enrollment in Phase 2 CALMA Alzheimer’s agitation trial, expects topline data in Q4 2026
  • IGC Pharma completed enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s dementia.
  • Topline results have not been presented; release is slated for Q4 2026.
  • Final patient dosing is expected to finish in early November, setting up database lock and unblinding.
  • The study is designed to show whether IGC-AD1 can reduce agitation versus placebo over a six-week treatment period.
  • Blinded safety reviews to date have supported continuing the trial without changes, with no treatment-related serious adverse events flagged so far.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609280800ACCESSWRNAPR_____1227682) on September 28, 2026, and is solely responsible for the information contained therein.